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A B S T R A C T   
Glioblastoma remains one of the most challenging and devastating cancers, with only a very small proportion of 
patients achieving 5-year survival. The current standard of care consists of surgery, followed by radiation therapy 
with concurrent and maintenance chemotherapy with the alkylating agent temozolomide. To date, this drug is 
the only one that provides a significant survival benefit, albeit modest, as patients end up acquiring resistance to 
this drug. As a result, tumor progression and recurrence inevitably occur, leading to death. Several factors have 
been proposed to explain this resistance, including an upregulated antioxidant system to keep the elevated 
intracellular ROS levels, a hallmark of cancer cells, under control. In this review, we discuss the mechanisms of 
chemoresistance -including the important role of glioblastoma stem cells-with emphasis on antioxidant defenses 
and how agents that impair redox balance (i.e.: sulfasalazine, erastin, CB-839, withaferin, resveratrol, curcumin, 
chloroquine, and hydroxychloroquine) might be advantageous in combined therapies against this type of cancer.   
1. Introduction 
Glioblastoma (GBM) is the most common and devastating malig-
nancy in the central nervous system. It is characterized by a great 
cellular pleomorphism with nuclear atypia, high mitotic activity, 
prominent microvascular proliferation, diffuse infiltration and central 
necrotic areas, combined with a profuse genomic instability and intense 
resistance to apoptosis (Furnari et al., 2007; Louis et al., 2016a). These 
hallmarks finally translate into the destruction of normal brain tissue 
and resistance to therapeutic agents, leading to death. Defined as grade 
IV astrocytoma according to the traditional World Health Organization 
(WHO) classification, the majority of GBM are primary tumors without a 
previous history of low-grade disease, rapidly arising de novo in elderly 
patients from normal glial cells, while a small percentage corresponds to 
secondary gliomas that progress from lower-grade tumors preferentially 
in younger patients (Ohgaki and Kleihues, 2007). 
Over the last two decades, molecular studies have revealed a broad 
constellation of epigenetic and genetic (mutations, deletions, amplifi-
cations and translocations) abnormalities in GBM, leading to significant 
changes in core signaling pathways, namely receptor tyrosine kinase 
(RTK)/Ras/phosphoinositide 3-kinase (PI3K), p53 and retinoblastoma, 
as well as in chromatin organization/remodeling and transcriptional 
regulation (The Cancer Genome Atlas (TCGA), 2008; Verhaak et al., 
2010; Brennan et al., 2013; Ceccarelli et al., 2017). Although some al-
terations are not limited to one type over another, it has become evident 
that both primary and secondary GBM evolve through different molec-
ular pathogenetic routes (Maher et al., 2006). Primary GBM typically 
show overamplification and mutation of the tyrosine kinase epidermal 
growth factor receptor (EGFR), often expressed as a truncated variant, 
EGFRvIII, that exhibits a constitutive activity and confers enhanced 
tumorigenicity. Activated EGFR triggers PI3K/protein kinase B (AKT), 
RAS/RAF/MAPK and Janus kinase (JAK)/signal transducer and acti-
vator of transcription (STAT) pathways, central mechanisms for con-
trolling cell survival, metabolism and proliferation (An et al., 2018). In 
addition, the tumor suppressor phosphatase and tensin homolog (PTEN) 
and cyclin-dependent kinase inhibitor A (CDKN2A) genes, encoding 
specific inhibitory proteins of the PI3K/AKT pathway and the 
cyclin-dependent kinases 4 and 6 (CDK4/6), respectively, are frequently 
mutated and/or deleted in these tumors (Knobbe et al., 2002; Vital et al., 
2010). In contrast, common alterations in secondary GBM include TP53 
and isocitrate dehydrogenase 1/2 (IDH1/2) mutations. In particular, the 
identification of IDH1 mutations (mainly R132H at the substrate binding 
site of IDH1) as diagnostic molecular markers of secondary GBM has 
allowed to unequivocally separate these two types as distinct tumor 
entities, otherwise histopathologically indistinguishable, thus suggest-
ing a link between specific metabolic alterations and glioma 
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development (Parsons et al., 2008; Nobusawa et al., 2009; Yan et al., 
2009). IDH mutations, which correlate with an increased overall sur-
vival, have been incorporated in the classification of glioblastomas 
(Louis et al., 2016b). 
Although much progress has been made in the elucidation of mo-
lecular events involved in the pathogenesis and malignancy of GBM, 
recent strategies against specific activated pathways in these tumors 
have shown no significant benefit in the clinical setting. Currently, 
numerous clinical trials with new proposed drugs and targets are un-
derway (Delgado-Martín and Medina, 2020). Therefore, most of the 
patients with newly diagnosed GBM will receive identical treatment, 
consisting of maximal feasible surgical resection followed by ionizing 
radiation plus concomitant and maintenance temozolomide (3-meth-
yl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; TMZ) chem 
otherapy (Fisher and Adamson, 2021; Tan et al., 2020). The addition of 
this alkylating agent to surgery and radiation has been shown to 
modestly increase the survival of these patients compared with post-
operative radiotherapy alone. Despite this aggressive treatment, the 
median survival is 12–16 months, with a 5-year survival of merely 5.5% 
after therapy (Stupp et al., 2005). Unfortunately, virtually all of them 
will inevitably experience tumor progression and recurrence due to 
intrinsic and acquired resistance of cancer cells to radiation and alky-
lating agents (Sarkaria et al., 2008). 
Emerging evidence suggests a crucial role of cancer stem cells (CSC) 
in GBM resistance and recurrence. According to the CSC hypothesis, the 
cellular hierarchy of the tumor is maintained by a fraction of cells 
(referred as CSC or tumor-initiating cells) which exhibit the main fea-
tures of stem cells: self-renewal and differentiation potential, that allow 
them to recapitulate the heterogeneity of the parental tumor from which 
they derive when injected orthotopically into mice (Hale et al., 2013; 
Singh et al., 2004). Glioblastoma stem cells (GSC) show greater resis-
tance to current radiotherapy and chemotherapy than their more 
differentiated progeny and the ability to repopulate the whole tumor 
after these treatments (Bao et al., 2006; Chen et al., 2012). Several 
mechanisms have been identified that may confer that resistance: be-
sides upregulated DNA repair capacity (Liu et al., 2006) and high EGFR 
activity (Pang et al., 2017), GSC exhibit enhanced drug efflux by 
ATP-binding cassette (ABC) transporters (Hirschmann-Jax et al., 2004), 
elevated levels of anti-apoptotic members of Bcl-2 family (Fanfone et al., 
2020) and reduced intracellular reactive oxygen species (ROS) accu-
mulation associated to higher expression of ROS scavenging systems 
(Kim et al., 2014). Various studies suggest that antioxidant capacity may 
be beneficial to cancer cells in order to minimize DNA, lipid membrane 
and protein damage, in a similar fashion to normal cells (Cockfield and 
Schafer, 2019). In this context, targeting redox homeostasis to tip the 
balance toward oxidative stress and induce cell death in cancer cells, 
which already have raised levels of ROS (Fig. 1), could be an effective 
anticancer approach (Pelicano et al., 2004; Reczek and Chandel, 2017). 
This review will focus on recent findings documenting the antioxidant 
systems that contribute to TMZ resistance in glioblastoma and the 
development of new combinatorial pro-oxidant therapies with TMZ that 
may serve to surpass this acquired resistance. 
2. Temozolomide and ROS generation 
TMZ is a small methylating imidazotetrazinone prodrug (molecular 
mass 194 Da) that is administered orally and, due to its lipophilic nature, 
it effectively crosses the blood-brain barrier (BBB), with a concentration 
in cerebrospinal fluid 30% of its plasma levels (Patel et al., 2003; 
Ostermann et al., 2004). Unlike other triazene compounds, it does not 
require hepatic metabolism, but spontaneously undergoes a hydrolysis 
cascade at physiologic pH to the unstable intermediate form 
5-(3-methyl)1-triazen-1-yl-imidazole-4-carboxamide (MTIC), which 
then breaks down into a highly reactive methyldiazonium cation –the 
active alkylating agent- and an inactive molecule, 5-aminoimidazole-4--
carboxamide (Darkes et al., 2002). The most studied cytotoxic effects of 
TMZ derive from the instantaneous reaction of methyldiazonium cation 
with accessible nucleophilic sites within the DNA molecule, causing its 
methylation at N7 and O6 positions of guanine and N3 position of 
adenine bases (Denny et al., 1994). 
In addition to DNA alkylation, oxidative stress induced by TMZ plays 
a decisive role in its cytotoxic effects (Fig. 2). It is well recognized that 
ROS has a “two-faced” character: although they act as key second 
messengers in intracellular signaling pathways, which induce and 
maintain the oncogenic phenotype of cancer cells when their levels are 
moderately increased, excessive ROS production damages proteins, 
lipids and DNA, triggering cellular senescence and apoptosis. Oxidative 
stress refers to the condition experienced by cells when ROS levels are 
increased or ROS scavenging capacity is diminished (Matés et al., 2008). 
There are three major types of ROS: superoxide anion radical (O2•− ), 
produced by the one-electron reduction of molecular oxygen via the 
mitochondrial electron transport chain or by NADPH oxidases; 
hydrogen peroxide (H2O2), generated in the superoxide dismutation 
reaction catalyzed by superoxide dismutase (SOD); and the very reactive 
hydroxyl radical (•OH), formed by the Fenton reaction (Schieber and 
Chandel, 2014). Most chemotherapeutics contribute to oxidative stress 
in cancer cells through amplification of ROS levels or inhibition of 
antioxidant systems (Yang et al., 2018). 
Zhang and coworkers demonstrated that GBM cells incubated with 
TMZ exhibited enhanced ROS production associated with DNA damage, 
leading to strong AMP-activated protein kinase (AMPK) upregulation, 
that could be inhibited with the antioxidant N-acetylcysteine (NAC) 
(Zhang et al., 2010). AMPK is a central metabolic sensor that becomes 
activated by the tumor suppressor liver kinase B1 (LKB1) and de-
termines cell fate through activation of pro-apoptotic p53 (Okoshi et al., 
2008). In response to TMZ treatment, LKB1-activated AMPK positively 
regulated p53 by its Ser-15 phosphorylation, inducing pro-apoptotic 
proteins Noxa and Bax. It also inhibited mammalian target of rapamy-
cin complex 1 (mTORC1), which caused downregulation of 
anti-apoptotic protein Bcl-2. The inhibitor O6-benzylguanine, which 
prevents O6-methylguanine-DNA methyltransferase (MGMT) from 
Fig. 1. Targeting redox homeostasis in chemoresistant GBM could be an 
effective anticancer approach. Dashed lines represent the balance between 
ROS elimination (left) and production (right) in normal (N), cancer (C) and 
chemoresistant cancer (R) cells. When ROS elimination is attenuated by inhi-
bition of antioxidant defense mechanisms, higher oxidative stress will result in 
cell death. 
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demethylating O6-methylguanine, the most lethal alkylation lesion in 
DNA, induced higher ROS generation and downstream AMPK activa-
tion. Thus, TMZ-mediated lesions act as upstream signals for apoptosis 
(Zhang et al., 2010). 
Oxidation of DNA bases, such as 8-oxo-7,8-dihydroguanine (8-oxoG) 
and 8-oxo-7,8-dihydroadenine, is another effect of TMZ (Lopes et al., 
2013). Reaction of ROS with DNA predominantly generates 8-oxoG. This 
lesion is recognized and excised primarily by 8-oxoG-DNA glycosylase 1 
(OGG1), which initiates the base excision repair (BER) mechanism (Ba 
and Boldogh, 2018). In order to identify genes that confer sensitivity to 
TMZ when silenced, Sobol laboratory performed a synthetic lethal small 
interfering RNA (siRNA) screen against more than 5000 genes in a 
TMZ-resistant GBM cell line. Several oxidative DNA glycosylases, 
including OGG1, were discovered to be involved in the resistance to 
TMZ, likely the result of an increased ROS production after incubation 
with the alkylating drug (Svilar et al., 2012). 
Oxidative stress causes lipid peroxidation, especially of poly-
unsaturated fatty acids, that may induce cell death. Malondialdehyde 
(MDA) and 4-hydroxy-2-nonenal (4-HNE) are two major lipid peroxi-
dation by-products that can covalently modify proteins of critical 
functional importance in the cell (Ayala et al., 2014). Enzymes of the 
aldehyde dehydrogenase (ALDH) 1 family catalyze the oxidation of 
intracellular aldehydes to their corresponding carboxylic acids (Muzio 
et al., 2012) and have been suggested as markers of therapy-resistant 
CSC, including GSC (Rasper et al., 2010). ALDH1A1 and ALDH1A3 
have been proposed as new components of resistance to TMZ. ALDH1A1 
inhibition or knock down restored the sensitivity of GBM cells to the 
alkylating drug. Furthermore, patients with GBM whose levels of 
ALDH1A1 were high had worse clinical outcomes compared with those 
with lower levels (Schäfer et al., 2012). An explanation of the role of 
ALDH1A3 in TMZ resistance has been recently presented. In this study, 
MDA and 4-HNE, resulting from lipid peroxidation, were increased in 
GBM cells after TMZ treatment and detoxified by ALDH1A3. Knocking 
down ALDH1A3 rendered these cells more sensitive to TMZ and addition 
of ROS scavengers restored their viability. Again, levels of this enzyme 
were significantly upregulated in recurrent GBM compared with pri-
mary tumors and higher expression correlated with poor clinical 
outcome (Wu et al., 2020). Two subtypes of GSC, expressing a different 
set of genes and signaling pathways, have been characterized by mRNA 
profiling: compared with proneural subtype (CD133+), GSC of mesen-
chymal (Mes) subtype (CD133-) showed a more aggressive behavior in 
vitro and as intracranial xenografts, and higher resistance to radiation. 
The inhibition of ALDH1A3 clearly diminished the growth of Mes GSC, 
indicating that the upregulation of this enzyme is critical for the main-
tenance of the Mes phenotype. In addition, the transition from proneural 
to Mes phenotype was induced by radiation and this process could be 
reversed by inhibition of ALDH1A3 (Mao et al., 2013). The aberrant 
expression of ALDH1A3 in Mes GSC is maintained by USP9X, a member 
of the ubiquitin-specific proteases family that deubiquitinates and pro-
tects ALDH1A3 from proteasomal degradation, leading to the preser-
vation of GSC features (Chen et al., 2019). 
3. Antioxidant mechanisms and TMZ chemoresistance 
A hallmark of most cancer cells is their deregulated redox homeo-
stasis, a consequence of increased metabolic rates, genetic alterations 
and harsh tumor microenvironment (Panieri and Santoro, 2016). The 
elevated levels of ROS are a common feature of cancer cells that 
contribute to tumor development and progression, but at the same time 
can have a harmful effect, ultimately leading to cell death (Liou and 
Storz, 2010; Wu, 2006). Cancer cells must rely on efficient antioxidant 
defense mechanisms for survival, making them more susceptible to 
further oxidative damage induced by exogenous agents that promote 
disproportionate ROS production or inhibit antioxidant systems (Gorrini 
et al., 2013; Trachootham et al., 2009). 
Both normal and cancer cells depend on the activation of the nuclear 
factor erythroid 2-related 2 (Nrf2) transcriptional network to neutralize 
the oxidative insult. The transcription factor Nrf2, a member of the cap 
‘n’ collar/basic leucine zipper (CNC/bZIP) protein family, is considered 
a master controller of redox homeostasis that drives the expression of an 
array of antioxidant defense genes and, as such, it is tightly regulated 
(Ma, 2013). According to its crucial protective role against ROS, it is not 
surprising that its activity is enhanced in GBM cells following treatment 
with TMZ. Thus, in recurrent tumor tissues after TMZ and irradiation, 
nuclear Nrf2 immunostaining was markedly increased compared with 
primary tumors and correlated negatively with the time to tumor 
recurrence (Cong et al., 2014). Nrf2 and related antioxidant response 
genes, detected in a CRISPR activation screen in GBM cancer cells, 
showed a robust negative correlation with GBM patient survival rates 
(Rocha et al., 2020). It has been shown that GSC require Nrf2 to main-
tain their proliferation and self-renewal capacities. When Nrf2 was 
downregulated by short hairpin RNA (siRNA), the expression levels of 
the pluripotency-associated markers polycomb complex protein BMI1, 
Sox2 (sex determining region Y-box 2) and Cyclin E were reduced and 
the proportion of cells in G2 phase increased. The self-renewal and 
tumorigenicity of GSC were also diminished in vivo after Nrf2 depletion 
(Zhu et al., 2013). Under normal conditions, Nrf2 is kept as an inactive 
cytoplasmic form through its binding to Kelch-like ECH-associated 
protein1 (Keap1), an adaptor for the Cullin-3-dependent E3 ubiquitin 
ligase complex, which ubiquitinates Nrf2 and targets it for proteolysis by 
26S proteasome. This constant mechanism of ubiquitination and 
degradation maintains Nrf2 at low levels (Cullinan et al., 2004). Upon 
Fig. 2. The double-edged sword effect of 
TMZ. The alkylating agent TMZ triggers 
apoptosis through a ROS burst associated to 
DNA damage but, eventually, induces the 
overexpression of antioxidant and DNA 
repair systems and a tighter mitochondrial 
coupling, leading to the acquisition of che-
moresistance and to tumor proliferation. 
ALDH1: aldehyde dehydrogenase 1; AMPK: 
AMP-activated protein kinase; ARE: antiox-
idant response element; BER: base excision 
repair; GLS: glutaminase; G6PD: glucose-6- 
phosphate dehydrogenase; GPx: glutathione 
peroxidase; GSR: glutathione reductase; 
GST: glutathione S-transferase; 4-HNE: 4- 
hydroxy-2-nonenal; IDH1: isocitrate dehy-
drogenase 1; LKB1: liver kinase B1; MDA: 
malondialdehyde; ME1: malic enzyme 1; mTORC1: mammalian target of rapamycin complex 1; Nrf2: nuclear factor erythroid 2-related 2; OGG1: 8-oxoG-DNA 
glycosylase 1; PGD: phosphogluconate dehydrogenase; SIRT3: sirtuin 3; SOD2: superoxide dismutase 2; TRAP1: TNF receptor-associated protein 1; Trx: thio-
redoxin; TrxR: thioredoxin reductase; xCT: subunit of the antiporter Xc ‾.   
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exposure to ROS or electrophilic chemicals, Keap1 is inactivated by 
modification of reactive cysteine thiols and the sequestration of Nrf2 is 
disrupted. This allows the accumulation of Nrf2 in the nucleus, where it 
heterodimerizes with the small musculoaponeurotic fibrosarcoma 
(sMAF) proteins and activates the transcription of cytoprotective genes 
containing ARE (antioxidant response element) regulatory sequences in 
their promoter regions (Yamamoto et al., 2018). 
Nrf2 tightly regulates the expression of enzymes involved in the 
biosynthesis of the tripeptide glutathione (γ-L-Glutamyl-L-cys-
teinylglycine, GSH), the most important intracellular antioxidant 
molecule that plays a critical function in ROS detoxification (Dringen, 
2000). In cancer cells, increased levels of GSH have been associated with 
drug resistance (Bansal, 2018). Nrf2 drives the expression of the cata-
lytic (Gclc) and modifier (Gclm) subunits of glutamate/cysteine ligase, 
the enzyme that catalyzes the rate-limiting step –the ATP-dependent 
ligation of glutamate and cysteine to form γ-glutamilcysteine- in the 
synthesis of GSH (Wild et al., 1999). The system Xc ‾, a 
cystine-glutamate antiporter that imports cystine into the cell, which is 
then reduced to cysteine in the cytosol, is essential for GSH biosynthesis 
(Lin et al., 2020). The gene Slc7a11 (solute carrier family 7 member 11), 
that encodes the xCT subunit of the antiporter Xc ‾, is a Nrf2 target 
(Sasaki et al., 2002). The glioblastoma TMZ-resistant cell line U-138MG 
showed a higher expression level of Nrf2 than the TMZ-sensitive cell line 
U-87MG. Because of Nrf2 induction after TMZ treatment, GSH levels 
were increased in GBM cells. Nrf2 silencing or GSH depletion by 
L-buthionine-sulfoximine (BSO), an inhibitor of GSH synthesis, greatly 
sensitized these cells to TMZ (Rocha et al., 2016). Disruption of Xc ‾ 
function by knocking down xCT expression in U-251MG GBM cells 
resulted in low levels of GSH, enhanced sensitivity to TMZ and pro-
nounced apoptosis. Conversely, overexpression of xCT increased the 
survival of cells under oxidative stress (Polewski et al., 2016). In addi-
tion, strong xCT expression in GBM patients correlated with shorter 
progression-free survival and overall survival (Takeuchi et al., 2013). 
GSH homeostasis also depends on the activity of glutaminase iso-
enzymes (GLS and GLS2), that catalyze the hydrolytic deamidation of 
glutamine to glutamate in the first step of glutaminolysis (Matés et al., 
2020). Besides their contribution to nucleotide and α-ketoglutarate 
biosynthesis, these isoenzymes are essential for GSH synthesis not only 
because the tripeptide contains glutamate, but also because this amino 
acid is equally necessary for the uptake of cystine (Matés et al., 2013). 
GLS is another target whose expression is upregulated by Nrf2 (Agye-
man et al., 2012). Higher expression of GLS, together with other two 
amino acids-metabolizing enzymes, asparagine synthetase and 
branched-chain-amino-acid aminotransferase (BCAT), was found to be 
associated with recurrence of GBM, shorter patient survival and resis-
tance to TMZ (Panosyan et al., 2016). Furthermore, GBM cells in vitro 
and in vivo may induce neuronal death in peritumoral regions through 
the release of neurotoxic concentrations of glutamate, facilitating the 
tumor expansion (Ye and Sontheimer, 1999; Takano et al., 2001). 
Glutamate also acts as an autocrine or paracrine signal that stimulates 
the migration of GBM cells mediated by Ca2+-permeable α-amino-3--
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Lyons 
et al., 2007). 
Several enzymes that utilize GSH to neutralize ROS and electro-
philes, and generate oxidized GSH (GSSG), are encoded by Nrf2 target 
genes (Chanas et al., 2002; Thimmulappa et al., 2002). Glutathione 
peroxidase (GPx) catalyzes the reduction of hydrogen peroxide (H2O2) 
and organic hydroperoxides to water or the corresponding alcohols, 
respectively, via oxidation of GSH, thus preventing the formation of the 
very reactive and damaging hydroxyl radical (Lubos et al., 2011). 
Glutathione S-transferases (GSTs) inactivate electrophilic compounds by 
conjugation to GSH (Allocati et al., 2018). The reduction of GSSG back 
to GSH is catalyzed by another Nrf2 target, glutathione reductase (GSR), 
that uses reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as the reducing factor. In GBM cell lines, GSR activity has been 
positively correlated with MGMT expression and, by regulating GSH 
levels and redox state balance, mediates TMZ resistance in a 
MGMT-independent manner. Knocking down GSR decreased GSH levels 
and resensitized TMZ-resistant cells to the alkylating drug, and the 
addition of GSH attenuated this effect. Conversely, overexpression of 
GSR dramatically lowered ROS levels and BSO reversed the resistance to 
TMZ (Zhu et al., 2018). The generation of NADPH is also modulated by 
Nrf2 through several targets: glucose-6-phosphate dehydrogenase 
(G6PD) and phosphogluconate dehydrogenase (PGD), both oxidative 
enzymes of the pentose phosphate pathway (PPP), malic enzyme 1 
(ME1) and IDH1 (Mitsuishi et al., 2012). In addition to the regulation of 
the GSH antioxidant system, Nrf2 controls the thioredoxin system 
(Hayes and Dinkova-Kostova, 2014), a critical antioxidant defense 
pathway composed of thioredoxin (Trx), NADPH and thioredoxin 
reductase (TrxR). Trx, with a dithiol-disulfide active site, acts as the 
major protein disulfide reductase and as an electron donor to peroxir-
edoxins for the reduction of H2O2. Then, TrxR reduces oxidized Trx back 
to its active dithiol form using NADPH as reduction equivalents (Arnér 
and Holmgren, 2000). Trx and TrxR are elevated in a variety of human 
cancers (Jia et al., 2019). Inhibition of Trx with the small-molecule in-
hibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) or by 
Trx-interacting protein (TNIP) overexpression sensitized TMZ-resistant 
GBM cells to cisplatin and TMZ and triggered apoptosis (Haas et al., 
2018). In line with these findings, high cytoplasmic TxrR expression was 
associated with poor overall survival in patients with GBM (Yao et al., 
2020). Interestingly, Trx binds directly to apoptosis signal-regulating 
kinase 1 (ASK1), a member of mitogen-activated protein (MAP) kinase 
family that plays a crucial role as a sensor stress involved in apoptotic 
signaling. Under oxidative stress, ASK1 dissociates from Trx and acti-
vates c-Jun N-terminal kinase (JNK) and p38-MAP kinase, thus resulting 
in induction of apoptosis (Saitoh et al., 1998). 
Another mechanism of chemoresistance independent of MGMT is 
mediated by specificity protein 1 (Sp1), a transcription factor that is 
highly expressed in a variety of cancers and associated with poor 
prognosis (Vizcaíno et al., 2015). Experiments in which MGMT-deficient 
GBM cells were incubated with TMZ, to make them resistant to this drug, 
showed a high increase in Sp1 levels and lower levels of intracellular 
ROS compared to those of their parental cells. Mitochondrial enzyme 
superoxide dismutase 2 (SOD2), a target of Sp1, was found to be upre-
gulated in the resistant cells. Treatment with Sp1 inhibitor mithromycin 
or SOD2 inhibitor diethyldithiocarbamate strongly sensitized these cells 
to TMZ and induced a significant accumulation of ROS. Similar results 
were obtained with a TMZ-resistant cell xenograft model (Chang et al., 
2017). Among significant mitochondria-related genes differentially 
expressed between parental and resistant GMB cells, SOD2 was a crucial 
factor in resistance and patient survival. SOD2 expression was also 
positively correlated with CSC features. Thus, its downregulation by 
siRNA decreased the expression levels of BMI1 and Sox2 (Chien et al., 
2019). The interplay between the mitochondrial proteins TNF 
receptor-associated protein 1 (TRAP1) and NAD+-dependent protein 
deacetylase sirtuin-3 (SIRT3), both overexpressed in GSC, reduced 
production of ROS by activating SOD2 and increased mitochondria 
respiratory capacity, essential for maintaining the stemness of GSC. 
Inhibiting either SIRT3 or TRAP1 led to ROS overproduction and cell 
death (Park et al., 2019). 
Mitochondrial DNA (mtDNA) and bioenergetics are also impacted by 
treatment with TMZ. In response to TMZ-induced stress, a mitochondrial 
adaptive response that contributes to chemoresistance, consisting of 
alterations in mtDNA and a dramatic remodeling of electron transport 
chain, is generated in glioblastoma cells. A significantly lower activity of 
respiratory complexes I and V and increased activity of cytochrome c 
oxidase (CcO) and complexes II-III were observed in a TMZ- 
chemoresistant stable GBM cell line. Suppression of CcO activity by 
pharmacological or genetic inhibition reversed chemoresistance to TMZ. 
Most importantly, these changes were recapitulated in TMZ-resistant 
GBM xenografts and recurrent GBM biopsies (Oliva et al., 2010). 
These resistant cells overcome TMZ-induced damage with a more 
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efficient mitochondrial coupling: decreased activity of complex I com-
bined with higher activity of CcO confer more efficient electron flux 
through the electron transport chain for ATP generation, resulting in low 
ROS production (Oliva et al., 2011). 
4. Combined pro-oxidant therapies against TMZ 
chemoresistance 
Numerous strategies have been developed to reverse the resistance to 
TMZ in GBM. One of the mechanisms of radiotherapy and chemotherapy 
is the excessive generation of ROS, to which tumor cells adapt by 
increasing their antioxidant defense systems. The combination of TMZ 
and agents with pro-oxidant properties that increases ROS production 
and override the intracellular antioxidant systems could improve ther-
apeutic outcomes in GBM treatment. In this section, we have focused on 
small molecules and natural compounds (Fig. 3), some of them tested in 
clinical trials, for which a molecular mechanism that causes enhanced 
oxidative stress has been described. Table 1 summarizes their main ef-
fects on GBM cell lines. 
System Xc ‾ appears to be the only feasible mechanism for cystine 
uptake in GBM cells, that depend on its overexpression for the synthesis 
of GSH (Chung et al., 2005). After disruption of xCT function, significant 
anti-cancer effects have been observed in different types of tumors, 
making this molecule a target for GBM therapy (Liu et al., 2020). Sul-
fasalazine (2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl] 
benzoic acid; SAS), a conjugate of 5-aminosalicylic acid and sulfapyr-
idine that has been approved for the treatment of several inflammatory 
diseases, is a potent xCT inhibitor (Gout et al., 2001) that depletes 
intracellular GSH levels in GBM cells -but not in astrocytes or neurons- 
and retards tumor growth in vitro and in vivo (Chung et al., 2005; Sehm 
et al., 2016). Although SAS also targets the nuclear factor kappa B 
(NF-κB) signaling pathway, several studies have demonstrated that its 
growth inhibitory effects in different cancer types are entirely attribut-
able to the blocking of cystine uptake via system Xc ‾ (Chung and Son-
theimer, 2009). SAS synergistically intensified the cytotoxic effect of 
TMZ on GBM cell lines and their association altered both cell cycle and 
antioxidant pathways (Ignarro et al., 2016). However, it should be noted 
that no apparent benefit was noticed in a phase I study of SAS without 
radiotherapy or chemotherapy (Robe et al., 2009), but these results are 
difficult to interpret due to the advanced disease of the patients enrolled 
(Sontheimer and Bridges, 2012). Again, a second clinical trial with SAS 
administered continuously with TMZ did not show positive outcome in 
progression-free survival and overall survival and was discontinued due 
to side effects (Takeuchi et al., 2014). Nevertheless, a study carried out 
with GBM xenografts found that SAS sensitized cancer cells to gamma 
knife radiosurgery (Sleire et al., 2015). 
Erastin (eradicator of RAS and small T antigen-expressing cells; 2-[1- 
[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxy-
phenyl)quinazolin-4-one), an oncogenic RAS-selective lethal small 
molecule (Dolma et al., 2003) that binds to voltage-dependent anion 
Fig. 3. Some inhibitors of antioxidant systems and compounds that synergize with TMZ in ROS generation. A: sulfasalazine; B: erastin; C: CB-839; D: DVD- 
445; E: PX-12; F: FX866; G: CHS-828; H: withaferin A; I: resveratrol; J: curcumin; K: chloroquine (R: CH3) and hydroxychloroquine (R: CH2OH); L: compound N45; 
M: polyphillin VII. 
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channels, has a stronger inhibitor effect on xCT than SAS. It induces an 
oxidative iron-dependent cell death mechanism distinct from apoptosis, 
necrosis or autophagy, known as ferroptosis. This mechanism is asso-
ciated to accumulation of lipid ROS by impaired cysteine-dependent 
synthesis of GSH and is prevented by iron chelation or inhibition of 
iron uptake (Dixon et al., 2012). GSH depletion by erastin also 
inactivates GPx-4, an essential regulator of ferroptosis that specifically 
neutralizes lipid peroxidation (Yang et al., 2014). The transsulfuration 
pathway, which is activated by treatment with TMZ, is another target of 
erastin. In addition to its uptake by system Xc ‾, cysteine can be syn-
thesized from homocysteine by the successive reactions of cystathionine 
β-synthase and cystathionine γ-lyase (CTH). In a study with several GBM 
cell lines treated with TMZ, a significant reduction of intracellular 
cysteine level (together with enhanced ROS levels) was observed 
following the inhibition of xCT by siRNA or SAS, although this was not 
accompanied by a marked decrease of GSH level. However, a stronger 
cytotoxic effect of TMZ was achieved by co-treatment with erastin, 
which suppressed cysteine uptake and CTH activity simultaneously 
(Chen et al., 2015). 
The biosynthesis of GSH can also be impaired by inhibition of GLS. 
GBM cells that harbor IDH mutations accumulate 2-hydroxyglutarate, 
an oncometabolite primarily derived from glutamine (Dang et al., 
2009). When compared to IDH-wild type cells, IDH-mutant cells treated 
with the GLS inhibitor BPTES showed a slower growth rate that could be 
restored by adding exogenous α-ketoglutarate (Seltzer et al., 2010). 
2-hydroxyglutarate inhibits the synthesis of glutamate by α-ketoglutar-
ate-dependent BCATs and, hence, the dependence of these cells on GLS 
isoenzyme for glutamate and GSH generation increases. Inhibition of 
GLS with CB-839 (N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thia-
diazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acet-
amide) caused GSH depletion and made IDH-mutant cells more 
susceptible to ROS-induced cytotoxicity (McBrayer et al., 2018). Based 
on these findings, a combination of CB-839 with radiation and TMZ is 
now being tested in patients with IDH-mutant gliomas (ClinicalTrials. 
gov Identifier: NCT03528642). In IDH-wild type GBM cells, the phar-
macological blockade of Notch pathway reduced the levels of GLS 
mRNA, which was reflected in reduced intracellular glutamate concen-
tration, suggesting that targeting GLS could be a feasible therapeutic 
strategy against GBM (Kahlert et al., 2016). 
As previously mentioned, the thioredoxin system seems to be another 
important player in chemoresistance. Besides Trx inhibition by PX-12, 
which sensitizes GBM cells to TMZ (Haas et al., 2018), novel in-
hibitors of TrxR1, such as DVD-445 (2-[[2-(tert-butylamino)-1-(4--
fluorophenyl)-2-oxoethyl]-methylamino]ethyl (E)-4-(4-fluorophenyl)- 
4-oxobut-2-enoate), have been developed (Jovanović et al., 2019) that 
show a synergistic effect in combination with TMZ. Treatment with 
these molecules potentiated the effect of TMZ through ROS accumula-
tion and disruption of mitochondrial membrane potential, significantly 
suppressing proliferation and invasion, and promoting cell death. 
Interestingly, they inhibited the P-glycoprotein 1 (P-gp), an ABC trans-
porter highly expressed in the endothelial cells of the BBB and in cancer 
cells. Due to its important role in excreting drugs and xenotoxins and, 
consequently, in multidrug resistance (MDR) in GBM, P-gp inhibition by 
TrxR1 inhibitors could suppress MDR phenotype and evade BBB 
(Jovanović et al., 2020). 
Nicotinamide phosphoribosyltransferase (NAMPT) is another 
promising therapeutic target in cancer (Sampath et al., 2015). Its 
overexpression in GBM tissues is correlated with poor prognosis (Guo 
et al., 2019). This enzyme catalyzes the rate-limiting step in the salvage 
pathway of nicotinamide adenine dinucleotide (NAD+) biosynthesis 
(Garten et al., 2015), that serves as a source of NADPH and hence of 
reducing equivalents for the GSH system (Heske, 2020). In human GBM 
cell lines (U-251MG and T98G), inhibition of NAMPT by drugs such as 
FK866 ((E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2- 
enamide) and CHS-828 (2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyr-
idin-4-ylguanidine) enhanced ROS and superoxide anion, synergistically 
activating the JNK signaling pathway, and increasing the TMZ-induced 
apoptosis through a caspase-1, caspase-3, and caspase-9 mechanism. 
Thus, FK866 and CHS-828 sensitize GBM cells to TMZ treatment (Feng 
et al., 2016). 
The currently used antimalarial drug chloroquine (4-N-(7-chlor-
oquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine; CQ) is an 
Table 1 
Main effects of pro-oxidant compounds on GBM cell lines.  
Compound GBM cell 
lines 










depletion of GSH after 
inhibition of cystine 
uptake induces 
apoptosis. 
ER stress and 
ferroptosis. 
Chung et al. 
(2005) 
Sehm et al. 
(2016) 
Erastin A-172, U- 
87MG, 
T98G 
5 xCT and CTH 
inhibitor: depletion of 
GSH. 






0.1 GLS inhibitor: 








10 Trx inhibitor: 
induction of apoptosis. 
Haas et al. 
(2018) 
DVD-445 U-87MG 8 Antiproliferative effect 
through inhibition of 












activation of JNK 
pathway. 



















Hori et al. 
(2015) 
Resveratrol SHG-44 10 G2/M arrest, cell 
differentiation and 
apoptosis through 
inhibition of AKT/ 
mTOR activity 
Yuan et al. 
(2012) 
Curcumin U-87MG 3.4 Apoptosis through 
disruption of AKT/ 
mTOR signaling. 
Yin et al. 
(2014) 




0.5–6 G2/M arrest and 
apoptosis through 
modulation of AKT/ 
mTOR and MAPK 
pathways; depletion of 
MGMT resentitizes 





















0.4–6 Apoptosis and 
autophagy through 




Pang et al. 
(2019) 
CTH: cystathionine γ-lyase; GLS: glutaminase; GSH: glutathione; ER: endo-
plasmic reticulum; IDH: isocitrate dehydrogenase; MGMT: O6-methylguanine- 
DNA methyltransferase; NAMPT: nicotinamide phosphoribosyltransferase; P- 
gp: P-glycoprotein 1; Trx: thioredoxin; TrxR: thioredoxin reductase; xCT: sub-
unit of the antiporter Xc ‾. 
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inhibitor of autophagic flux and sensitizes GBM cells to TMZ by pre-
venting autophagosome clearance dependent of glucose-regulated pro-
tein 78/binding-immunoglobulin protein (GRP78/BiP) and increasing 
the expression of one of the components of the endoplasmic reticulum 
stress-mediated apoptotic pathway, the CCAAT enhancer-binding pro-
tein (C-EBP) homologous protein/growth arrest and DNA damage 153 
(CHOP/GADD-153) (Golden et al., 2014). GRP78 acts as a prosurvival 
arm of the unfolded protein response (UPR) which maintains endo-
plasmic reticulum integrity, assists in autophagosome formation and 
promotes chemoresistance by interfering with apoptotic pathways. Its 
expression is elevated in GBM and inversely correlated with patient 
survival (Lee et al., 2008). CQ also enhanced TMZ cytotoxicity by 
increasing mitochondrial ROS and inhibiting mitochondrial autophagy 
(Hori et al., 2015). Both CQ and its derivative hydroxychloroquine have 
been tested in several clinical trials (Rosenfeld et al., 2014; Abbruzzese 
et al., 2017). 
In addition, several natural compounds, such as curcumin ((1E, 6E)- 
1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione), 
resveratrol (5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol), 
compound N45 (pennogenin-3-O-α-L-rhamnopyranosyl-(1–4)-[α-L- 
rhamnopyranosyl-(1–2)]-β-D-glucopyranoside), polyphyllin VII (pen-
nogenin-3-O-α-L-rhamnopyranosyl(1–4)-α-L-rhamnopyranosyl(1–4)- 




have been tested in GBM cells in combination with TMZ. Curcumin (an 
inexpensive and well-tolerated natural bioactive compound found in the 
spice turmeric, Curcuma longa L.) and TMZ caused a synergistic effect on 
ROS generation, enhancing TMZ-induced apoptosis in U-87MG GBM 
cells. Mechanistically, curcumin increased TMZ-disrupted AKT/mTOR 
signaling. Noteworthy, the combined treatment of curcumin and TMZ 
significantly diminished the phosphorylation of AKT, Bcl2-associated 
agonist of cell death (BAD) and mTOR in the extracts derived from U- 
87MG xenograft tumor tissues (Yin et al., 2014). Resveratrol, a naturally 
occurring polyphenolic molecule, abundant in grapes, peanuts and red 
wine, showed additive effect when combined with TMZ in human GBM 
cell line SHG44. Resveratrol and TMZ synergistically inhibited cell 
migration, induced the G2/M arrest and cell differentiation, enhancing 
ROS generation, and activating AMPK signaling pathway. Of note, 
resveratrol also increased TMZ-induced inhibition of the growth of 
orthotopic implanted GBM in nude mice (Yuan et al., 2012). Compound 
N45, a steroidal saponin isolated from the rhizomes of Paris vietnamensis 
(Takht.) H.Li, demonstrated oxidative cytotoxicity and suppressed the 
proliferation of U-87MG GBM cells and TMZ-resistant U-87MG GBM 
(U-87R) cells by evoking mitochondrial apoptosis through ROS/PI3-
K/AKT signal pathway. Additionally, N45 decreased the drug-resistance 
by downregulation of NF-κB p65 to constrict MGMT in U-87R cells 
(Zhang et al., 2020). Another steroidal saponin, polyphyllin VII from 
Paris polyphylla Sm., induced apoptosis and autophagic cell death in 
U-87MG and U-251MG cells, through inhibition of AKT/mTORC1 ac-
tivity via ROS generation. Combined treatment with TMZ showed a 
synergistic cytotoxic effect. Furthermore, polyphyllin VII reduced TMZ 
resistance by suppressing the expression of MGMT (Pang et al., 2019). 
Similarly, the steroidal lactone withaferin A, isolated from several 
genera of Solanaceae plants, elevated ROS levels and prevented cell 
proliferation in several GBM cell lines by G2/M arrest and apoptosis 
largely through modulation of AKT/mTOR and MAPK pathways. Addi-
tion of the ROS scavenger NAC abrogated these effects. In combination 
with TMZ, it resensitized TMZ-resistant cells by MGMT depletion 
(Grogan et al., 2014). 
5. Conclusions 
Effective therapies against GBM, one of the most challenging can-
cers, remain elusive. Despite combined action of TMZ and inhibitors of 
antioxidant systems showing excellent results in GBM cell lines and in 
vivo models, only a few of them have been assayed in clinical trials with 
no substantial progress. This may be due to several factors: 1) the 
extensive GBM heterogeneity, both intratumoral and intertumoral; 2) 
the presence of GSC as crucial drivers of recurrence and resistance; 3) 
the activation of efficient drug efflux systems; 4) the dynamic interaction 
with a complex microenvironment; 5) the poor permeability to drugs 
due to BBB. Additional efforts will be necessary to test known pro- 
oxidant compounds and find new molecules that synergistically in-
crease therapeutic effect of TMZ combinatory treatments against GBM. 
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